Perrigo Company plc (0Y5E.L)
USD 26.02
(-4.23%)
USD 26.02
(-4.23%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.14 Billion USD | -0.82% |
| 2022 | 1.15 Billion USD | 12.75% |
| 2021 | 1.02 Billion USD | -15.0% |
| 2020 | 1.2 Billion USD | 24.08% |
| 2019 | 967.3 Million USD | 10.17% |
| 2018 | 878 Million USD | 8.81% |
| 2017 | 806.9 Million USD | 1.5% |
| 2016 | 795 Million USD | -5.23% |
| 2015 | 838.9 Million USD | 32.82% |
| 2014 | 631.6 Million USD | -10.27% |
| 2013 | 703.9 Million USD | 28.58% |
| 2012 | 547.45 Million USD | 8.28% |
| 2011 | 505.57 Million USD | 12.63% |
| 2010 | 448.87 Million USD | 16.65% |
| 2009 | 384.79 Million USD | -3.79% |
| 2008 | 399.97 Million USD | 35.53% |
| 2007 | 295.11 Million USD | -2.58% |
| 2006 | 302.94 Million USD | 10.98% |
| 2005 | 272.98 Million USD | 56.66% |
| 2004 | 174.25 Million USD | 8.69% |
| 2003 | 160.32 Million USD | 3.03% |
| 2002 | 155.61 Million USD | -3.41% |
| 2001 | 161.11 Million USD | 26.92% |
| 2000 | 126.93 Million USD | 0.0% |
| 1999 | - USD | -100.0% |
| 1998 | 181.5 Million USD | 12.38% |
| 1997 | 161.5 Million USD | 2.87% |
| 1996 | 157 Million USD | -3.98% |
| 1995 | 163.5 Million USD | 20.4% |
| 1994 | 135.8 Million USD | 5.76% |
| 1993 | 128.4 Million USD | 20.56% |
| 1992 | 106.5 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.12 Billion USD | -1.72% |
| 2024 Q2 | 1.11 Billion USD | -0.45% |
| 2023 Q1 | 1.18 Billion USD | 2.84% |
| 2023 FY | 1.14 Billion USD | -0.82% |
| 2023 Q3 | 1.14 Billion USD | -1.54% |
| 2023 Q2 | 1.16 Billion USD | -1.31% |
| 2023 Q4 | 1.14 Billion USD | -0.75% |
| 2022 FY | 1.15 Billion USD | 12.75% |
| 2022 Q3 | 1.08 Billion USD | 0.52% |
| 2022 Q2 | 1.07 Billion USD | 5.59% |
| 2022 Q1 | 1.02 Billion USD | 0.22% |
| 2022 Q4 | 1.15 Billion USD | 6.0% |
| 2021 Q3 | 1.09 Billion USD | -2.1% |
| 2021 Q1 | 1.13 Billion USD | -5.34% |
| 2021 Q4 | 1.02 Billion USD | -6.62% |
| 2021 FY | 1.02 Billion USD | -15.0% |
| 2021 Q2 | 1.11 Billion USD | -1.78% |
| 2020 Q1 | 930.8 Million USD | -3.77% |
| 2020 Q2 | 1.03 Billion USD | 11.16% |
| 2020 Q4 | 1.2 Billion USD | 9.04% |
| 2020 Q3 | 1.1 Billion USD | 6.38% |
| 2020 FY | 1.2 Billion USD | 24.08% |
| 2019 Q4 | 967.3 Million USD | -2.34% |
| 2019 Q2 | 940.5 Million USD | 3.02% |
| 2019 Q1 | 912.9 Million USD | 3.97% |
| 2019 FY | 967.3 Million USD | 10.17% |
| 2019 Q3 | 990.5 Million USD | 5.32% |
| 2018 Q3 | 885.3 Million USD | 0.17% |
| 2018 Q2 | 883.8 Million USD | 4.74% |
| 2018 Q4 | 878 Million USD | -0.82% |
| 2018 Q1 | 843.8 Million USD | 4.57% |
| 2018 FY | 878 Million USD | 8.81% |
| 2017 Q1 | 800.2 Million USD | 0.65% |
| 2017 FY | 806.9 Million USD | 1.5% |
| 2017 Q4 | 806.9 Million USD | -1.83% |
| 2017 Q3 | 821.9 Million USD | 0.46% |
| 2017 Q2 | 818.1 Million USD | 2.24% |
| 2016 Q2 | 894.6 Million USD | 2.97% |
| 2016 Q3 | 884.6 Million USD | -1.12% |
| 2016 Q4 | 795 Million USD | -10.13% |
| 2016 FY | 795 Million USD | -5.23% |
| 2016 Q1 | 868.8 Million USD | 2.89% |
| 2015 FY | 838.9 Million USD | 32.82% |
| 2015 Q3 | 888 Million USD | 5.85% |
| 2015 Q4 | 844.4 Million USD | -4.91% |
| 2015 Q2 | 838.9 Million USD | 31.7% |
| 2015 Q1 | 637 Million USD | -0.75% |
| 2014 FY | 631.6 Million USD | -10.27% |
| 2014 Q2 | 631.6 Million USD | -8.93% |
| 2014 Q4 | 641.8 Million USD | -2.28% |
| 2014 Q3 | 656.8 Million USD | 3.99% |
| 2014 Q1 | 693.5 Million USD | -1.25% |
| 2013 Q1 | 684.74 Million USD | 7.19% |
| 2013 FY | 703.9 Million USD | 28.58% |
| 2013 Q4 | 702.3 Million USD | -2.65% |
| 2013 Q3 | 721.4 Million USD | 2.49% |
| 2013 Q2 | 703.9 Million USD | 2.8% |
| 2012 FY | 547.45 Million USD | 8.28% |
| 2012 Q4 | 638.79 Million USD | 6.68% |
| 2012 Q3 | 598.82 Million USD | 9.38% |
| 2012 Q2 | 547.45 Million USD | -7.2% |
| 2012 Q1 | 589.94 Million USD | 1.6% |
| 2011 Q4 | 580.66 Million USD | 3.09% |
| 2011 Q1 | 494.27 Million USD | 2.17% |
| 2011 Q2 | 505.57 Million USD | 2.29% |
| 2011 Q3 | 563.25 Million USD | 11.41% |
| 2011 FY | 505.57 Million USD | 12.63% |
| 2010 Q4 | 483.78 Million USD | 4.89% |
| 2010 Q2 | 448.87 Million USD | 7.49% |
| 2010 Q1 | 417.58 Million USD | 0.27% |
| 2010 FY | 448.87 Million USD | 16.65% |
| 2010 Q3 | 461.24 Million USD | 2.76% |
| 2009 Q4 | 416.47 Million USD | 8.46% |
| 2009 Q2 | 384.79 Million USD | 0.47% |
| 2009 Q3 | 383.98 Million USD | -0.21% |
| 2009 Q1 | 383.01 Million USD | -11.08% |
| 2009 FY | 384.79 Million USD | -3.79% |
| 2008 Q1 | 356.9 Million USD | 9.48% |
| 2008 Q3 | 448.38 Million USD | 12.1% |
| 2008 FY | 399.97 Million USD | 35.53% |
| 2008 Q2 | 399.97 Million USD | 12.07% |
| 2008 Q4 | 430.71 Million USD | -3.94% |
| 2007 Q1 | 310.27 Million USD | -3.83% |
| 2007 FY | 295.11 Million USD | -2.58% |
| 2007 Q2 | 295.11 Million USD | -4.89% |
| 2007 Q3 | 314.59 Million USD | 6.6% |
| 2007 Q4 | 326 Million USD | 3.63% |
| 2006 Q4 | 322.62 Million USD | -1.2% |
| 2006 Q3 | 326.53 Million USD | 7.79% |
| 2006 Q2 | 302.94 Million USD | 10.7% |
| 2006 Q1 | 273.66 Million USD | 4.11% |
| 2006 FY | 302.94 Million USD | 10.98% |
| 2005 Q3 | 269.69 Million USD | -1.2% |
| 2005 Q4 | 262.85 Million USD | -2.54% |
| 2005 Q2 | 272.98 Million USD | -9.39% |
| 2005 Q1 | 301.27 Million USD | 80.82% |
| 2005 FY | 272.98 Million USD | 56.66% |
| 2004 Q2 | 174.25 Million USD | 12.53% |
| 2004 FY | 174.25 Million USD | 8.69% |
| 2004 Q3 | 181.83 Million USD | 4.35% |
| 2004 Q4 | 166.61 Million USD | -8.37% |
| 2004 Q1 | 154.84 Million USD | 8.57% |
| 2003 Q2 | 160.32 Million USD | 2.74% |
| 2003 Q3 | 149.87 Million USD | -6.52% |
| 2003 Q1 | 156.04 Million USD | 1.67% |
| 2003 FY | 160.32 Million USD | 3.03% |
| 2003 Q4 | 142.62 Million USD | -4.83% |
| 2002 Q4 | 153.47 Million USD | -6.25% |
| 2002 Q2 | 155.61 Million USD | 7.04% |
| 2002 Q1 | 145.37 Million USD | -10.08% |
| 2002 FY | 155.61 Million USD | -3.41% |
| 2002 Q3 | 163.7 Million USD | 5.2% |
| 2001 Q4 | 161.67 Million USD | -5.52% |
| 2001 Q3 | 171.11 Million USD | 6.21% |
| 2001 Q2 | 161.11 Million USD | 22.5% |
| 2001 Q1 | 131.51 Million USD | 8.27% |
| 2001 FY | 161.11 Million USD | 26.92% |
| 2000 FY | 126.93 Million USD | 0.0% |
| 2000 Q2 | 126.93 Million USD | -8.78% |
| 2000 Q1 | 139.14 Million USD | -18.48% |
| 2000 Q4 | 121.47 Million USD | -3.65% |
| 2000 Q3 | 126.07 Million USD | -0.68% |
| 1999 FY | - USD | -100.0% |
| 1999 Q3 | 190.5 Million USD | 0.0% |
| 1999 Q4 | 170.7 Million USD | -10.39% |
| 1999 Q2 | - USD | -100.0% |
| 1999 Q1 | 205.4 Million USD | -2.93% |
| 1998 Q4 | 211.6 Million USD | 2.57% |
| 1998 Q3 | 206.3 Million USD | 13.66% |
| 1998 FY | 181.5 Million USD | 12.38% |
| 1998 Q2 | 181.5 Million USD | -7.82% |
| 1998 Q1 | 196.9 Million USD | 7.77% |
| 1997 Q4 | 182.7 Million USD | 5.3% |
| 1997 FY | 161.5 Million USD | 2.87% |
| 1997 Q3 | 173.5 Million USD | 7.43% |
| 1997 Q2 | 161.5 Million USD | -0.62% |
| 1997 Q1 | 162.5 Million USD | -1.04% |
| 1996 FY | 157 Million USD | -3.98% |
| 1996 Q1 | 172.8 Million USD | -2.81% |
| 1996 Q2 | 157 Million USD | -9.14% |
| 1996 Q3 | 158.8 Million USD | 1.15% |
| 1996 Q4 | 164.2 Million USD | 3.4% |
| 1995 Q3 | 171.6 Million USD | 4.95% |
| 1995 Q2 | 163.5 Million USD | 3.15% |
| 1995 Q1 | 158.5 Million USD | 7.09% |
| 1995 FY | 163.5 Million USD | 20.4% |
| 1995 Q4 | 177.8 Million USD | 3.61% |
| 1994 Q4 | 148 Million USD | 2.92% |
| 1994 FY | 135.8 Million USD | 5.76% |
| 1994 Q1 | 139.2 Million USD | 1.09% |
| 1994 Q2 | 135.8 Million USD | -2.44% |
| 1994 Q3 | 143.8 Million USD | 5.89% |
| 1993 Q3 | 137.1 Million USD | 6.78% |
| 1993 FY | 128.4 Million USD | 20.56% |
| 1993 Q1 | 126.3 Million USD | 7.31% |
| 1993 Q2 | 128.4 Million USD | 1.66% |
| 1993 Q4 | 137.7 Million USD | 0.44% |
| 1992 Q3 | 105.7 Million USD | -0.75% |
| 1992 Q1 | 99 Million USD | 26.28% |
| 1992 FY | 106.5 Million USD | 0.0% |
| 1992 Q2 | 106.5 Million USD | 7.58% |
| 1992 Q4 | 117.7 Million USD | 11.35% |
| 1991 Q4 | 78.4 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -9388.523% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -5880.814% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -1811.183% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -11654.585% |
| bluebird bio, Inc. | 22.91 Million USD | -4877.966% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -40343.105% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -195.673% |
| Myriad Genetics, Inc. | 20.1 Million USD | -5576.119% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -2878.851% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -1373.879% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 86.287% |
| Waters Corporation | 516.23 Million USD | -121.004% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 77.577% |
| Biogen Inc. | 2.52 Billion USD | 54.859% |
| Nektar Therapeutics | 16.1 Million USD | -6985.895% |
| Dynavax Technologies Corporation | 53.29 Million USD | -2040.927% |
| Illumina, Inc. | 587 Million USD | -94.361% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -10899.807% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -2609.333% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | -3.045% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -10273.704% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 55.788% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -1638.567% |
| FibroGen, Inc. | 41.56 Million USD | -2644.857% |
| Agilent Technologies, Inc. | 1.03 Billion USD | -10.66% |
| OPKO Health, Inc. | 65.69 Million USD | -1636.609% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -1179.811% |
| Exelixis, Inc. | 17.32 Million USD | -6486.042% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 55.503% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -7438.157% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 46781.669% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | -54.426% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -3913.72% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -253.374% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -14659.379% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -794.115% |
| Blueprint Medicines Corporation | 21.22 Million USD | -5275.772% |
| Insmed Incorporated | 83.24 Million USD | -1270.483% |
| TG Therapeutics, Inc. | 39.82 Million USD | -2764.927% |
| Incyte Corporation | 62.97 Million USD | -1711.758% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -246.884% |